The stock price has plummeted, and it has fallen steeper than a cliff!It plummeted from $26 to $65 yuan, it's really scary. It was actually because the pig industry lost to the so-called "pig cycle", which was a big blow.The stock price has repeatedly fallen sharply, from 26 yuan all the way to 65 yuan, the pig industry lost to the "pig cycle", and the net profit of more than six years of listing actually fell to more than 3.1 billion yuan.
As of December 21, Aonong Biotech (603363) opened low again, and the stock price once hit the fall limit, and finally reached 65 yuan**, a decrease of 934%。The day before, on December 20, Aonong Biotech also fell rapidly in early trading, once hitting the fall limit, with a decline of nearly 7% on the day.
An investor left a message asking for help, asking suspiciously: "Who can tell me what to do?"The heavy position has lost nearly 30 points, and I am a little confused, should I continue to hold it, or should I cut the meat decisively?Cover the position but don't have enough funds!Another investor replied that there are many who have lost more than 50%, stay calm!
It is observed that since mid-July 2022, the share price of Aonong Biotech has dropped from more than 26 yuan per share to about 6 yuan at present, and the cumulative decline during the period has reached an astonishing 75%.
On the evening of December 20, Aonong Biotech issued an announcement disclosing that as of now, the shares of the company's controlling shareholders, actual controllers and persons acting in concert have been judicially frozen and judicially marked a total of 5185330,000 shares, accounting for 13 of its total shares16%。At the same time, as of December 15, the controlling shareholder, the actual controller and its persons acting in concert have pledged a total of 3 shares of the company5.2 billion shares, accounting for 89 percent of its total holdings35%, accounting for 40% of the company's total share capital43%。
On December 13, Aonong Biotech issued an announcement officially announcing that it had reached a strategic cooperation agreement with Dabeinong Group. According to the agreement, Aonong Investment, as the controlling shareholder of the company, will sign an investment cooperation agreement with Dabeinong Group. Dabeinong Group plans to purchase the assets of Aonong Biotech through equity or asset transfer, and the proposed investment amount will not exceed 600 million yuan.
Aonong Biotech particularly emphasized that the above agreement is only a preliminary intention at present, and there are still some uncertainties about the content and progress of the specific implementation. However, once the strategic cooperation agreement is successfully implemented, it will have a positive impact on the company's cash flow position and promote the company's business development. At the same time, the successful advancement and completion of the investment cooperation agreement will lead to a change of control of the company.
Founded in April 2011, the company is a high-tech agricultural, animal husbandry and food enterprise oriented by standardization, standardization, intensification and industrialization, mainly engaged in feed, pig raising, food and other industries. In September 2017, the company was successfully listed on the Shanghai Stock Exchange.
It is worth mentioning that in 2020, benefiting from the significant year-on-year increase in the number of live pigs slaughtered and the company's pig sales remained high due to the impact of supply and demand, Aonong Biotech achieved a revenue of 115 in 2020200 million yuan, a year-on-year increase of 9898%。The net profit attributable to the parent company reached 57.3 billion yuan, a year-on-year increase of more than 1,800%, setting a peak of profitability since listing.
However, fate is really playing with people, and agreed to achieve "pigs", but they fell into the "pig" pit!A closer look shows that the number of live pigs in 2021 is significantly higher than that of the previous year, while the number of feed raw materials is soaring.
In addition, although the pig industry of Aonong Biotech is in a stage of rapid development, the breeding capacity has not yet been fully released, and at the same time, the fixed expenses are the majority, resulting in high short-term costs......
This situation had a direct impact on Aonong's performance in 2021, despite the increase in revenue to 180400 million yuan, but the net profit attributable to the parent company in the same period suffered a huge loss, reaching 152 billion yuan;
The same will be true in 2022, the cyclical fluctuations of the pig breeding industry and the fact that the company's breeding scale is initially formed but the breeding cost is still declining, resulting in a full-year revenue of 216100 million yuan, but the net profit attributable to the parent company lost more than 1 billion yuan again!
With the passage of time, the arrival of 2023 has not brought any signs of improvement for Aonong Biotech. Pigs continue to be sluggish, while the main feed raw materials such as corn and soybean meal have remained at a relatively high level, which has once again brought great challenges and huge pressure on the company's business. In the first three quarters alone, the company's revenue has reached 151800 million yuan, and the net profit attributable to the parent company lost 12 again9 billion yuan ......
All this can't help but make people think deeply, since its listing in 2017, the cumulative net profit of Aonong Biotech has lost more than 3.1 billion yuan ......
As of the end of the third quarter of 2023, Aonong's debt ratio has soared to 8941%, which is the highest level in history, which is quite worrying. The company's short-term borrowings are as high as 405.1 billion yuan, but the monetary funds on hand are only 299.5 billion yuan, the situation has become extremely grim. This financial pressure cannot be ignored and poses a huge challenge to the company's future operations.